CA3054839C - Polypeptides and uses thereof for treatment of a fibrosis disease - Google Patents

Polypeptides and uses thereof for treatment of a fibrosis disease Download PDF

Info

Publication number
CA3054839C
CA3054839C CA3054839A CA3054839A CA3054839C CA 3054839 C CA3054839 C CA 3054839C CA 3054839 A CA3054839 A CA 3054839A CA 3054839 A CA3054839 A CA 3054839A CA 3054839 C CA3054839 C CA 3054839C
Authority
CA
Canada
Prior art keywords
seq
polypeptide
amino acid
fibrosis
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3054839A
Other languages
English (en)
French (fr)
Other versions
CA3054839A1 (en
Inventor
De Wei
Yi Ding
Xiaomei Li
Wen Yu
Xiaohong Chen
Ling Xiao
Rui Chen
Ling Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Huitai Biomedicine Co Ltd
Original Assignee
Chengdu Huitai Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710115604.4A external-priority patent/CN106860855B/zh
Priority claimed from CN201710677602.4A external-priority patent/CN109384830B/zh
Application filed by Chengdu Huitai Biomedicine Co Ltd filed Critical Chengdu Huitai Biomedicine Co Ltd
Publication of CA3054839A1 publication Critical patent/CA3054839A1/en
Application granted granted Critical
Publication of CA3054839C publication Critical patent/CA3054839C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA3054839A 2017-03-01 2018-02-28 Polypeptides and uses thereof for treatment of a fibrosis disease Active CA3054839C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710115604.4 2017-03-01
CN201710115604.4A CN106860855B (zh) 2017-03-01 2017-03-01 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN201710677602.4A CN109384830B (zh) 2017-08-09 2017-08-09 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN201710677602.4 2017-08-09
PCT/CN2018/077492 WO2018157807A1 (zh) 2017-03-01 2018-02-28 多肽、多肽片段及其衍生物与应用

Publications (2)

Publication Number Publication Date
CA3054839A1 CA3054839A1 (en) 2018-09-07
CA3054839C true CA3054839C (en) 2023-08-29

Family

ID=63369746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3054839A Active CA3054839C (en) 2017-03-01 2018-02-28 Polypeptides and uses thereof for treatment of a fibrosis disease

Country Status (9)

Country Link
US (2) US12011475B2 (enExample)
EP (1) EP3590527A4 (enExample)
JP (1) JP6965362B2 (enExample)
KR (1) KR102368159B1 (enExample)
AU (1) AU2018227737B2 (enExample)
CA (1) CA3054839C (enExample)
IL (1) IL268971B2 (enExample)
SG (1) SG11201907914QA (enExample)
WO (1) WO2018157807A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240306T1 (hr) * 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
CN112386678B (zh) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 多肽或其衍生物的应用
JP7892764B2 (ja) * 2021-08-11 2026-07-21 イミュニティーバイオ インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
CN119384427A (zh) * 2022-06-23 2025-01-28 成都倍特新启生物医药有限责任公司 肽抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20060270618A1 (en) 2001-12-18 2006-11-30 Dorian Bevec Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
AU2008303928A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of NF-KAPPAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of EG HBV infection
WO2009043525A2 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
JP2014506117A (ja) * 2010-11-24 2014-03-13 エフ．ホフマン−ラ ロシュ アーゲー 軽度の炎症を検出するための方法
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
CN104313028A (zh) 2014-09-30 2015-01-28 北京生科东方科技有限公司 抗类风湿关节炎的小肽基因及其生产方法
CN105061600A (zh) 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 类风湿因子IgA抑制多肽及其应用
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用

Also Published As

Publication number Publication date
IL268971A (en) 2019-10-31
US12011475B2 (en) 2024-06-18
KR102368159B1 (ko) 2022-03-03
IL268971B1 (en) 2023-09-01
WO2018157807A1 (zh) 2018-09-07
US20240390450A1 (en) 2024-11-28
JP2020509061A (ja) 2020-03-26
AU2018227737B2 (en) 2021-04-01
IL268971B2 (en) 2024-01-01
CA3054839A1 (en) 2018-09-07
EP3590527A1 (en) 2020-01-08
AU2018227737A2 (en) 2020-01-30
AU2018227737A1 (en) 2019-10-17
KR20190125373A (ko) 2019-11-06
JP6965362B2 (ja) 2021-11-10
US20220072082A1 (en) 2022-03-10
EP3590527A4 (en) 2021-01-06
SG11201907914QA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
CN106860855B (zh) 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
US20240390450A1 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
JP7597398B2 (ja) 組換え神経成長因子のための組成物及び方法
US20220280594A1 (en) Application of polypeptide or derivative thereof
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
WO2021252910A2 (en) C-type natriuretic peptides and methods thereof in treating acute lung injury
EP3166623B1 (en) Multi-drug delivery system and uses thereof
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
US20260115261A1 (en) Collagen peptide-based medicament compositions and uses thereof
HK40015944A (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
KR102629203B1 (ko) 별아교세포 선택적 펩타이드가 결합된 나노입자 및 이의 용도
Liu et al. Bioactive nanofiber hydrogel acts on VEGF and VEGF receptor to unleash Inhibition effects on corneal neovascularization
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
Peng et al. PEGylated thymosin β4 is a thiol‐site‐specific prodrug treating myocardial infarction in vivo
WO2021117754A1 (ja) Ｄｎａ損傷の抑制又は修復剤
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190920

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260210